KELLY GOVRO: Open Payments
NPI 1467638544 · SAINT CHARLES, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,889 in 172 payments from 17 companies in 2025. Trend: 2023 $3,244 · 2024 $3,069 · 2025 $2,889
Food & beverage: $2,779Education: $109
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $409 |
| ABBVIE INC. | 34 | $350 |
| Teva Pharmaceuticals USA, Inc. | 11 | $294 |
| Otsuka America Pharmaceutical, Inc. | 17 | $290 |
| Vanda Pharmaceuticals Inc. | 20 | $278 |
| Axsome Therapeutics, Inc. | 17 | $262 |
| Alkermes, Inc. | 12 | $204 |
| E.R. Squibb & Sons, L.L.C. | 9 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Janssen Pharmaceuticals, Inc | 7 | $151 |
Products named: INGREZZA, REXULTI, VRAYLAR, FANAPT, Auvelity, ARISTADA, COBENFY, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
